α-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-α,α′-diol, Albuterol
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
Beilstein/REAXYS Number:
EC Number:
MDL number:
PubChem Substance ID:
Pricing and availability is not currently available.

Quality Level


methanol: complete 50 mg/ml, clear, colorless to yellow



SMILES string




InChI key


Gene Information

human ... ADRB2(154)

Looking for similar products? Visit Product Comparison Guide


Salbutamol was administered to primate model to study the bronchoconstriction in chronic allergic asthma.20 Salbutamol was used as a standard for rapid pharmacokinetic screening of human plasma samples using HPLC.21


25, 50 mg in glass insert
100, 250 mg in poly bottle

Biochem/physiol Actions

Salbutamol is a β2 adrenoceptor agonist with short acting bronchodilation and anti-inflammatory effects. It relaxes the airway smooth muscles and inhibits bronchoconstriction induced by adenosine-5′ -monophosphate (AMP).1 Salbutamol is particularly effective in treatment of asthma as it provides immediate relief.2
β2-adrenoceptor agonist

Features and Benefits

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.


Exclamation mark

Signal Word


Hazard Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

Hazard Codes


Risk Statement


Safety Statement



NONH for all modes of transport

WGK Germany


Certificate of Analysis
Certificate of Origin
Huib A M Kerstjens et al.
The Lancet. Respiratory medicine, 3(5), 367-376 (2015-02-16)
In patients with severe asthma, tiotropium improves lung function and exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting β2 agonists. We aimed to assess the safety and efficacy of tiotropium in patients with moderate asthma who were symptomatic...
James Fingleton et al.
The Journal of allergy and clinical immunology, 136(3), 601-609 (2015-03-10)
Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and...
M Reza Maleki-Yazdi et al.
Respiratory medicine, 108(12), 1752-1760 (2014-12-03)
Combinations of inhaled long-acting bronchodilator therapies such as muscarinic antagonists and β2-agonists may be more effective than monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). This study was a 24-week, Phase III, multicenter, randomized, blinded, double-dummy, parallel-group study...
L Gnatiuc et al.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 19(1), 21-30 (2014-12-19)
Increasing access to essential respiratory medicines and influenza vaccination has been a priority for over three decades. Their use remains low in low- and middle-income countries (LMICs), where little is known about factors influencing use, or about the use of...
Ashley Woodcock et al.
Chest, 144(4), 1222-1229 (2013-07-13)
The combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting β2 agonist, is under development as a once-daily treatment of asthma and COPD. The aim of this study was to compare the efficacy of...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.